BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE ...

SOUTH SAN FRANCISCO, CA, USA I January 06, 2025 I Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the ...

Human metapneumovirus, usually known for respiratory infections, can—though rarely—trigger life-threatening brain inflammation.

Per- and polyfluorinated alkyl substances (PFAS) earn their "forever chemical" moniker by persisting in water, soil and even the human brain. This unique ability to cross the blood-brain barrier and ...

Per- and polyfluorinated alkyl substances (PFAS) earn their "forever chemical" moniker by persisting in water, soil and even ...

Researchers have found that per- and polyfluorinated alkyl substances (PFAS) alter the expression of specific genes in ...

On a recent visit to Washington DC, Ho sat down with GEN Editorial Director Kevin Davies, PhD, to discuss Denali’s progress ...

The gene therapy for an undisclosed central nervous system disease is based on JCR's delivery technology and Modalis' epigenome editing platform.

Environmental pollution from micro and nanoplastics (MNPs) poses significant global health risks due to their durability and ...